February 1, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Cutting-edge Nitto Denko Biomedical R&D Wins Government Support

Tokyo, Dec 1, 2008 (JCN) - An R&D project on a epoch-making Molecular Targeting Drug Delivery (MTD) system being pursued jointly by Japan's leading diversified materials manufacturer Nitto Denko and a team led by one of the world's leading medical researchers, Professor Yoshiro Niitsu of Sapporo Medical University, has been selected to receive Japanese government-sponsored assistance, both financial and otherwise, for Fiscal Year 2008 ending March 2009, Nitto Denko announced today.

Extending over a two-to-three-year period with grants of up to ca. 300 million yen (3 million US dollars) per year, the financial grant under the assistance program is expected to boost the acceleration of the MTD research project, Nitto Denko said.

The assistance for the joint R&D will be forthcoming under New Energy and Industrial Technology Development Organization (NEDO)'s "Translational Research Promotion (TRP) Project" designed to bridge the basic research and clinical research stages. NEDO is Japan's semi-governmental administrative agency responsible for boosting the competitiveness of Japan's industrial technology by identifying core technology seeds of the future and promoting technology R&D at various stages of development by coordinating and focusing the total strength of the country's governmental, industrial and academic communities. Programs under NEDO's auspices extend to a broad range of industries, from energy & environment to electronics, biotechnology, aerospace, fuel cells, etc.

NEDO's TRP project system aims to realize a swift practical application and popularization of medical technologies commensurate with the progress of the science involved, and focuses on the four fields, Drug discovery, Diagnostic technology, Regenerative and Cell medicine, and Therapy equipment.

For FY08, application for TRP assistance was sought in the fields of Drug discovery and Diagnostic technology, and as a result of rigorous deliberation, eight projects including the Nitto Denko/Prof. Niitsu project were chosen out of a total of 88 applications. Taking the opportunity of this latest development.

By Saroj Shrestha Staff Writer

Copyright © 2015 JCN. All rights reserved. A division of Japan Corporate News Network KK.

 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Nitto Denko Corporation News  
  Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US  (Oct 10, 2014)
  Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation  (Apr 24, 2014)
  Nitto Denko Launches New Encapsulation Sheet for LED  (Feb 15, 2013)
  Nitto Denko Develops Optical Touch-screen Technology for 'Smart' Stationery  (July 12, 2011)
  Nitto Denko Group Wins RO Membrane Orders for Big Australian Seawater Desalination Plant Project  (June 25, 2010)
  Nitto Denko, Kobe University Selected for Joint Bioethanol R&D by NEDO  (Sept 11, 2009)
  Nitto Denko Invests S$10 Million To Pioneer Organic Electronic Device Research In Singapore  (Dec 1, 2008)
  Nitto Denko Invests S$10 Million To Pioneer Organic Electronic Device Research In Singapore  (Dec 1, 2008)
  Cutting-edge Nitto Denko Biomedical R&D Wins Government Support  (Dec 1, 2008)
  Nitto Denko Plans Water R&D Center in Singapore; New Center to be Development Hub for Cutting-edge Water Treatment Technologies  (June 25, 2008)

CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)